Evidence map›Paper›PMID 34806016›Full record

ArticleNAR cancer2021

NAD

Jianfeng Li, Kate M Saville, Md Ibrahim, Xuemei Zeng, Steve McClellan, Anusha Angajala, Alison Beiser, Joel F Andrews, Mai Sun, Christopher A Koczor and 7 more

Open access · goldAbstract read
In one paragraph

Article in NAR cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  12. Poly-ADP-ribosylation dynamics, signaling, and analysis.Environmental and molecular mutagenesis · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Balancing NADCellular and molecular life sciences : CMLS · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Jianfeng LiMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Kate M SavilleMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Md IbrahimMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Xuemei ZengBiomedical Mass Spectrometry Center, University of Pittsburgh Schools of the Health Sciences, Pittsburgh, PA 15213, USA.
Steve McClellanMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Anusha AngajalaMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Alison BeiserMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Joel F AndrewsMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Mai SunBiomedical Mass Spectrometry Center, University of Pittsburgh Schools of the Health Sciences, Pittsburgh, PA 15213, USA.
Christopher A KoczorMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Jennifer ClarkMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Faisal HayatMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Mikhail V MakarovMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Anna WilkMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Nathan A YatesBiomedical Mass Spectrometry Center, University of Pittsburgh Schools of the Health Sciences, Pittsburgh, PA 15213, USA.
Marie E MigaudMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Robert W SobolMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.ORCID https://orcid.org/0000-0001-7385-3563
USA Mitchell Cancer Institute · USUniversity of Pittsburgh · US

Funding

Research Project 3P01ES028949 · NIEHS · FLORIDA GULF COAST UNIVERSITY · PI PARSONS, MICHAEL · 2018 to 2024
$3.8M
Novel approaches to enhance tumor cell cytotoxicity of alkylating agentsR01CA148629 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SOBOL, ROBERT W · 2010 to 2021
$3.4M
Investigating genetic ancestry influences on oral cavity and laryngeal cancer survival disparitiesR01CA238061 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI RAGIN, CAMILLE C., SOBOL, ROBERT W · 2019 to 2023
$3.4M
Measuring genomic DNA damage and DNA repair capacity in longitudinal population samples - a step towards precision preventionU01ES029518 · NIEHS · UNIVERSITY OF SOUTH ALABAMA · PI SOBOL, ROBERT W · 2018 to 2022
$2.7M
NCI NIH HHS R01 CA148629NCI NIH HHS R01 CA238061NIEHS NIH HHS P01 ES028949NIEHS NIH HHS U01 ES029518
6 · The paper itself

Abstract

Elevated expression of the DNA damage response proteins PARP1 and poly(ADP-ribose) glycohydrolase (PARG) in glioma stem cells (GSCs) suggests that glioma may be a unique target for PARG inhibitors (PARGi). While PARGi-induced cell death is achieved when combined with ionizing radiation, as a single agent PARG inhibitors appear to be mostly cytostatic. Supplementation with the NAD

Identifiers

PMID34806016
PMCPMC8600031
OpenAlexW3213601110

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.